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Introduction
In medically fit patients with advanced esophageal cancer, the
National Comprehensive Cancer Network (NCCN) recommends
chemotherapy with or without radiation [1]. Unfortunately, de-
spite undergoing chemoradiation and surgery, 5-year survival
for patients with locally advanced esophageal cancer ranges
from only 20% to 40% [2, 3]. In a randomized trial of 386 pa-
tients, a pathologic complete response (CR) was observed in
only 29% of patients who underwent neoadjuvant chemother-
apy with carboplatin and paclitaxel along with concurrent
radiotherapy at 41.4 Gray (Gy) [4]. Even after undergoing sur-
gery, median survival was only 49.4 months.
Dysphagia is the most common symptom in patients with
advanced esophageal cancer. It contributes to malnourishment
and weight loss, and may delay initiation of chemoradiation.
Neoadjuvant cryotherapy improves dysphagia and may impact
remission rates in advanced esophageal cancer
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Background and study aims Liquid nitrogen spray cryo-
therapy (LNSC) can provide rapid dysphagia relief, and is
postulated to stimulate a local antitumor immune re-
sponse. The aim of this prospective pilot clinical trial was
to evaluate the safety and efficacy of LNSC when adminis-
tered prior to chemoradiotherapy.
Patients and methods Treatment-naïve adult patients
with dysphagia at the time of biopsy-proven squamous car-
cinoma or adenocarcinoma of the esophagus were pro-
spectively enrolled at two tertiary medical centers. Patients
underwent a single session of LNSC. The primary outcome
measure was change in dysphagia at 1 and 2 weeks post-
cryotherapy. A secondary outcome measure was clinical
complete response rate (CR) following chemoradiotherapy.
Results Twenty-five patients were screened, of whom 21
patients were eligible and enrolled. There were seven with
metastatic and 14 with locally advanced cancer. The primary
outcome of dysphagia improvement of ≥1 point occurred in
15/21 patients (71%) at 1 week, and 10/20 patients (50%) at
2 weeks. The median dysphagia score improved by 1 at 1
week (P=0.0003), and 0.5 at 2 weeks (P=0.02). Six of nine
patients (67%) with locally advanced cancer who completed
chemoradiation did not have residual tumor cells on muco-
sal biopsy, and five of nine patients (56%) had a clinical CR.
There were no serious cryotherapy-related complications.
Conclusions LNSC provided safe and effective palliation for
esophageal cancer patients who presented with dysphagia
at index diagnosis. Its combination with chemoradiotherapy
did not lead to any serious toxicity. Our study provides a sci-
entific rationale for pursuing larger clinical trials addressing
synergistic effects of combining LNSC with chemoradiation.
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Self-expandable metal stents can rapidly palliate dysphagia, but
their use in the neoadjuvant setting is associated with a high
morbidity rate, increased risk of serious toxicities, and possibly
decreased survival [5]. Furthermore, 50% of these stents mi-
grate during neoadjuvant chemotherapy.
Chemoradiation does improve dysphagia, but the effects are
not observed for several weeks after the initial dose of radiation
is administered. Enteral feeding via gastrostomy or jejunostomy
tubes can ameliorate malnutrition, but they do not palliate dys-
phagia. Furthermore, gastrostomy tubes can render the gastric
conduit unsuitable for esophagectomy [6]; jejunostomy tubes
require surgery performed under general anesthesia.
Liquid nitrogen spray cryotherapy (LNSC) is a relatively new
modality for treatment of esophageal neoplasia. During LNSC,
liquid nitrogen at super cold temperatures (–76 to –158 °C) is
sprayed directly on the tumor for 20 to 40 seconds [7, 8]. The
tissue is then allowed to thaw before spraying again for 20 to
40 seconds. Typically, two to four freeze-thaw cycles of liquid
nitrogen are administered. These cycles cause intracellular dis-
ruption and ischemia, which leads to ablation of tumor tissue
[9]. In addition, early observations that freezing a primary le-
sion may cause untreated sites of disease to regress suggest
that cryoablation may stimulate an antitumor immune re-
sponse [9–11].
Several studies have documented the safety and effective-
ness of LNSC in Barrett’s esophagus and superficial esophageal
cancer [12–14]. Retrospective series and case reports suggest
that LNSC is also safe and efficacious in patients with advanced
esophageal cancer [5, 13, 15–27]. However, no study has pro-
spectively assessed the efficacy of LNSC in the neoadjuvant or
definitive chemoradiation settings. The aims of this prospective
pilot clinical trial were to evaluate: (1) safety of LNSC adminis-
tered prior to chemotherapy and radiation; (2) efficacy of LNSC
at palliating dysphagia at index diagnosis; and (3) efficacy of
combined LNSC plus chemoradiation at inducing a clinical or




Adult patients with dysphagia at the time of biopsy-proven
squamous carcinoma or adenocarcinoma of the esophagus
who were treatment-naïve were prospectively enrolled at two
tertiary medical centers. One site was a tertiary veterans hospi-
tal (Hunter Holmes McGuire Veterans Affairs Medical Center)
and the other was an academic medical center (Washington
University Medical Center). The study was registered on clini-
caltrials.gov (identifier NCT02606396). The institutional review
board at both institutions approved the study. Exclusion criteria
were as follows: inability to provide informed consent, absence
of dysphagia, alternative etiology for dysphagia, inability to
pass gastroscope and orogastric decompression tube into the
stomach, and uncorrected coagulopathy (international normal-
ized ratio > 2 or platelet count < 50,000/mm3). Baseline vari-
ables recorded were as follows: age, gender, ethnicity, tumor
histology and TNM stage, location and length of tumor, pres-
ence or absence of critical organ invasion (i. e. aorta, trachea,
heart, and vertebral body), Eastern Cooperative Oncology
Group (ECOG) performance status, and baseline Mellow-Pinkas
dysphagia score, a standardized and validated measure of dys-
phagia in patients with esophageal cancer [18] (▶Table1).
Cryotherapy treatment
Cryoablation was performed under monitored anesthesia
either at the same time as the initial staging endoscopic ultra-
sound (EUS) procedure or as a separate procedure if EUS was
not indicated (i. e. metastatic disease at diagnosis). Following
upper endoscopy (EGD), a modified orogastric decompression
tube was passed over a guidewire through the mouth into the
stomach before initiation of LNSC. The tube contains decom-
pression ports spanning the distal 12 inches to allow gas vent-
ing of both the stomach and the esophagus during treatment.
The tube was connected to continuous suction throughout the
cryotherapy procedure.
LNSC was performed with low-pressure liquid nitrogen
(< 5psi) at 25W using a cryotherapy catheter passed through
the working channel of the endoscope. Two cycles of cryospray
ablation of normal mucosa for 20 seconds each produces a
mean depth of injury of 5.4mm, which is sufficient to reach
the submucosa [19]. Published studies on LNSC in superficial
esophageal cancer have typically reported spraying each site
three times for 20 seconds during each cycle [13]. In clinical
practice, a dose of 30 seconds during each cycle is more fre-
quently used in patients with esophageal cancer [17]. Our pro-
tocol was to ablate for 20 to 40 seconds after a bed of frost was
visible during each cycle (▶Fig. 1). The protocol allowed for up
to three cycles per site. During each cycle, a surface area of
approximately 2 to 3 cm2 was targeted. Up to three sites were
treated during each session. Tissue thawing was verified be-
tween cycles by waiting at least 60 seconds before retreatment,
and by observing a return to baseline color of the tissue.
After the procedure was completed, patients were moni-
tored in the recovery unit for at least 30 minutes. Patients
were discharged after monitoring if they met the endoscopy
unit’s standard discharge criteria. All patients received stand-
ardized discharge instructions, which included clear liquids for
72 hours, avoiding hard crunchy foods for a week, and avoid-
ance of anticoagulants and nonsteroidal anti-inflammatory
▶Table 1 Mellow-Pinkas Dysphagia Score.
Score Symptom
0 No Dysphagia
1 Dysphagia to Solids
2 Dysphagia to semi-solids (grits or other foods like
oatmeal, cream of wheat, rice)
3 Dysphagia to liquids
4 Dysphagia to saliva
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drugs unless the cardiopulmonary risk of discontinuing these
agents was deemed unacceptable.
Data collection
A member of the study team contacted each patient 1, 2, and 4
weeks after the cryotherapy procedure to assess for procedure-
related adverse events (AEs) as outlined in the American Socie-
ty of Gastrointestinal Endoscopy (ASGE) Lexicon [20] and
change in Mellow Pinkas dysphagia score.
A data safety monitoring committee met every 6 months to
adjudicate AEs. In patients with locally advanced disease, EGD
was performed at least 6 weeks after completing chemoradia-
tion to maximize diagnostic accuracy by minimizing the poten-
tial for sampling non-viable tumor cells [21]. The endoscopist
obtained a minimum of eight mucosal biopsies to assess for
presence of residual tumor cells. In addition, post-treatment
positron emission tomography (PET) findings were reviewed
with the multidisciplinary oncology team to assess for elevated
standardized uptake values (SUV) in regional lymph nodes, dis-
tant lymph nodes, and distal organs. In patients with locally
advanced cancer, data collection ended after post-chemoradia-
tion PET scan and biopsy/surgical explant results were available.
We also reviewed all patients’ records to assess for recurrence
and survival immediately prior to preparation of the manu-
script.
Statistical analyses
The primary outcome was change in dysphagia score compared
to baseline at 1 and 2 weeks after cryotherapy. The minimum
clinically important difference was defined as a 1-point im-
provement in pre-and post-cryotherapy dysphagia score. In a
series of six post-chemoradiation patients who underwent 12
sessions of cryotherapy while receiving chemotherapy, we
found that dysphagia score improved in all patients, and medi-
an improvement in dysphagia score was 1.6 [22]. Absent any
concurrent local or systemic therapy, we hypothesized that
cryotherapy would result in a 1-point improvement in dyspha-
gia score in at least 50% of patients. We further hypothesized
that 10% of patients would have had a similar improvement in
dysphagia due to dilation effect from the gastroscope and/or
echoendoscope alone. Based on a confidence level of 95% and
power of 80%, we calculated a sample size of at least 17 pa-
tients would be needed. Therefore, we planned to enroll 20 pa-
tients for this study. Wilcoxan rank sum test was used to calcu-
late if the change in dysphagia scores from baseline were statis-
tically significant [23].
Secondary outcomes for the study were the proportion of
patients with locally advanced disease who completed chemo-
radiation and had a local complete response (defined by
absence of residual tumor cells on mucosal biopsy or surgical
explant), and pathologic or clinical complete response (defined
as absence of residual tumor cells on mucosal biopsy or surgical
explant, and absence of regional or distal metastases on PET
scan).
Results
A total of 25 patients were screened for inclusion in the study
(CONSORT flowchart, ▶Fig. 2). Three patients were excluded
because they denied any symptoms of dysphagia. One patient
was excluded after enrollment because he was found to have a
superficial cancer in the setting of a large paraesophageal her-
nia. In this patient, the paraesophageal hernia was deemed
responsible for the dysphagia symptoms. Twenty-one patients
were eventually included in the study (14 with locally advanced
cancer, and 7 with metastatic cancer). Patients were pre-
dominantly elderly, white, and male with comorbid conditions
(▶Table2). Seventeen patients (65%) were over age 65 and
five patients (24%) were over age 80 at diagnosis. EUS was per-
formed in 16 patients. In 14 of 16, the tumor extended past the
muscularis propria into the adventitia (T3 tumor), and in two of
six patients the tumor extended to the muscularis propria (T2
▶ Fig. 1 a Esophageal tumor causing luminal obstruction. b Spray cryotherapy is continued for 20 to 40 seconds after a bed of frost has formed.
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tumor). The proximal extent of the tumor was less than 30 cm
from the incisors in 4 patients.
A median of two sites were treated during each cryotherapy
session (range 1 to 3), and a median of four ablations were per-
formed during each session (range 3 to 8). Nearly all ablations
lasted 30 seconds after a bed of frost had formed. Six patients
required esophageal dilation to permit passage of either the
echoendoscope or the gastroscope along with the orogastric
decompression tube. There were no serious AEs related to the
cryotherapy procedure. One patient experienced mild chest dis-
comfort that resolved within 20 minutes without any interven-
tion. One patient experienced worsening dysphagia 24 hours
after the procedure. An EGD was repeated, which demonstrated
tumor slough obstructing the lumen. After the slough was
pushed into the stomach, the patient’s dysphagia improved
compared to baseline. Dysphagia improvement of ≥1 point oc-
curred in 15 of 21 patients (71%) at 1 week, and 10 of 20 patients
(50%) at 2 weeks. For the primary outcome, median dysphagia
score improved by 1 at 1 week (P=0.0003), and 0.5 at 2 weeks
(P=0.02). Dysphagia improvement of ≥1 point was observed in
seven of 17 patients at 4 weeks.
Among patients who did not undergo dilation, dysphagia
improvement of ≥1 point occurred in 11 of 15 patients (73%)
at 1 week, and nine of 14 patients (64%) at 2 weeks. Change in
dysphagia was not significantly different between patients with
adenocarcinoma vs. squamous cell carcinoma (P=1.0 at 1
week, 0.08 at 2 weeks). Change in dysphagia was not signifi-
cantly different between patients with locally advanced and
metastatic cancer (P=0.7 at 1 week, 0.58 at 2 weeks). One pa-
tient with metastatic disease died within 2 weeks of the proce-
dure, and another two patients with metastatic disease died
within 4 weeks. One patient with metastatic disease required
stent placement. Therefore, dysphagia score was not obtained
for one patient at 2 weeks, and 4 patients at 4 weeks. None of
the deaths were deemed by the data safety monitoring board
to be related to the cryotherapy procedure.
Among the 14 patients with locally advanced disease, treat-
ment allocation was as follows: two patients proceeded directly
to surgery without neoadjuvant chemoradiation; one patient
with locally advanced disease did not receive chemotherapy be-
cause of coexisting myelodysplastic syndrome; one patient had
poor performance status (ECOG 3) that precluded chemoradia-
tion; one patient elected to halt chemoradiation prematurely;
and nine patients completed chemoradiation. Chemo-
radiotherapy was initiated a median of 27 days after cryother-
apy.
Of the nine patients who completed chemoradiation, only
two patients required enteral feeding and no patient under-
went esophageal stenting. Both patients who required enteral
feeding had at least at 1-point improvement in dysphagia at 1
and 2 weeks, but had worsening dysphagia at 4 weeks after
the LNSC procedure was completed. In both patients, jejunos-
tomy tube feeding was required to maintain nutritional intake
during chemoradiation. Median weight loss from diagnosis to
the end of chemoradiation was 12 lb (median total body weight
loss of 5%), and median decline in albumin was 0.4 g/dL. Medi-
an radiation dose was 50.4 Grays (range 26.6 to 66.6 Grays).
The chemotherapy regimen selected for all patients with locally
advanced cancer was carboplatin and paclitaxel.
A local complete response (CR) was seen in 67% of patients
who completed chemoradiation, and 56% had a clinical CR.
None of the patients underwent surgery after completing che-
moradiation. All seven patients with metastatic cancer died
during the study period. Among the patients who initiated che-
moradiation, 80% patients with a clinical CR were alive but only
40% of patients who did not have CR were alive at the end of
the study period.
▶Table 2 Baseline characteristics (n = 21).
Tumor histology Adenocarcinoma 15
Squamous cell carcinoma  6





Median age (years) 71 (range 49–87)
Race 5 black, 16 white
Gender 20 Male; 1 Female
Median ASA status 3 (range 1 to 4)
Median ECOG performance
status
1 (range 0 to 3)
Median tumor length (cm) 5 (range 2 to 12)
Mean baseline dysphagia
score
1.76 (range 1 to 4)
Median BMI 25 (range 16 to 35)
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative
Oncology Group; BMI, body mass index
Biopsy proven esophageal cancer, screened for eligibility
(n = 25)
Excluded (n = 4)
•  No dysphagia at baseline (n = 3)
•  Dysphagia due to para-esophageal






▶ Fig. 2 Study flowchart.
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Discussion
In locally advanced esophageal cancer, response to induction
chemoradiotherapy is the single most important predictor of
prognosis [24]. Dysphagia and malnourishment are common
in advanced esophageal cancer, and can impair ability to initi-
ate and complete chemoradiation. Despite the advanced age
and comorbidities of our study population, cryotherapy did
not result in any serious treatment-related toxicity, and signifi-
cantly improved dysphagia. Among the patients with locally
advanced cancer who initiated chemoradiation, only 20% re-
quired enteral feeding; 90% of these patients were able to
complete chemoradiotherapy. Total body weight loss during
chemoradiation was similar to what has been described with
enteral feeding and stents [25]. Improved dysphagia has also
been reported with other endoscopic ablation modalities such
as photodynamic therapy (PDT) and Nd:YAG laser therapy. In a
randomized trial, Mellow-Pinkas dysphagia score improved by
at least 1 point in less than half the patients at 1 week, and at
1 month despite multiple sessions [26]. More importantly, in
contrast to LNSC, a substantial proportion of patients undergo-
ing ablation with these modalities experienced a treatment-
related AE (almost 50% of patients with PDT and 15% with Nd:
YAG) [26]. An esophageal perforation or a pleural effusion oc-
curred in 10% of PDT-treated patients and 8% of Nd:YAG-treat-
ed patients. While our preliminary data suggest that LNSC may
be more effective and safer than these other modalities, larger
studies are necessary to corroborate these findings. In our
study, patients underwent a single session of LNSC. Whether
multiple sessions can increase palliative efficacy of LNSC with-
out increasing risk of AEs in the neoadjuvant setting also re-
mains to be determined.
In the landmark Dutch CROSS study, neoadjuvant chemo-
radiation improved survival compared to surgery alone in local-
ly advanced esophageal cancer [4]. In a randomized trial for
locally advanced squamous cell carcinoma, neoadjuvant che-
moradiation alone provided similar survival benefit compared
to chemoradiation and surgery [24]. Yet even with chemo-
radiotherapy, 5-year survival in locally advanced esophageal
cancer remains less than 50% [4]. Only 29% of patients have a
pathologic CR after chemoradiation [4]. Interestingly in our
study, a complete CR was observed in a much higher propor-
tion of patients than has been documented in the literature. A
local CR was observed in 67% of patients, and 56% of patients
had a complete CR (no tumor on post-treatment mucosal biop-
sy or PET scan). These findings raise the possibility that cryo-
therapy could work synergistically with chemoradiation to in-
crease remission rates. Some investigators have postulated
that cryotherapy could stimulate a host antitumor response.
Immune responses against malignant cells in the tumor micro-
environment are believed to influence prognosis of solid tu-
mors [27]. Tumor infiltrating lymphocytes (TILs) of various sub-
types represent the host to tumor reaction. Specific TIL subsets
are thought to promote either tumor progression or regression
[28]. For instance, in colorectal cancer, CD8+ T cells have been
shown to mediate antitumor immunity and to lyse tumors di-
rectly by recognizing the major histocompatibility complex
class 1 (MHC1) that is present on most tumor cells [28]. In
contrast, T-regulatory cells (TREGs) and Forkhead box P3+
(FOXp3+) T cells suppress the immune response of other cells,
that is, they affect the inflammatory process indirectly [29].
Given the paucity of data on cryotherapy on the host tumor im-
mune response, our group has recently developed a protocol to
compare TILs and immunohistochemistry in pretreatment and
post-treatment tumor samples among patients who received
cryotherapy and chemoradiation to matched patients who re-
ceived chemoradiation alone.
This is the first prospective clinical trial of cryotherapy in
esophageal cancer, and the first study assessing its safety and
usefulness in the definitive or neoadjuvant chemoradiation set-
ting. Our findings need to be interpreted in the context of cer-
tain limitations. Nearly all patients were elderly males, which
may limit overall generalizability. Given that this was a pilot
study without a control group and because six of 21 patients
underwent esophageal dilation, the efficacy of cryotherapy at
palliating dysphagia may have been overestimated. Although
patients were permitted to try solid food as tolerated after 72
hours, they were asked to avoid hard, crunchy foods for a
week. These instructions may offer one explanation for why im-
provement in dysphagia was lower at 2 weeks than at 1 week.
Remission rate was a secondary outcome and was assessed
based on data from only nine patients, so the high clinical CR
rates require further validation. Given the morbidity of esopha-
gectomy, and the advanced age and frailty of our patient popu-
lation, none of the patients underwent surgery after chemo-
radiation. As a result, CR was based on mucosal biopsy and PET
scan (clinical CR) rather than surgical explant and PET scan
(pathologic CR), which could overestimate remission rate [30].
Our general practice is to perform surveillance endoscopy with
biopsy every 3 months for the first year after chemoradiation in
patients with negative biopsies who do not undergo surgery.
During surveillance, one patient had a recurrent tumor within
the first year after chemoradiation was completed. If long-
term response is considered as a surrogate measure for patho-
logic CR, then the remission rate would actually be 44%.
Conclusion
In summary, spray cryotherapy improves dysphagia when ad-
ministered at initial diagnosis of esophageal cancer. Its use
prior to chemoradiation does not appear to increase toxicity.
Further study is required to understand whether cryotherapy
has any impact on the host tumor immune response [9, 10].
Our study provides a scientific rationale to pursue larger clinical
trials addressing synergistic effects of combining cryotherapy
with chemoradiation.
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